NCT03717402

Smartphone Technology to Alleviate Malignant Pain (STAMP)

Completed NA Results posted Last updated 5 June 2023

What this trial tests

NA trial testing Intervention Participants in Cancer in 20 participants. Completed in 1 May 2022.

Timeline

1 November 2018

Primary endpoint
1 May 2022

1 May 2022

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	20
Start date	1 November 2018
Primary completion	1 May 2022
Estimated completion	1 May 2022
Sites	1 location across United States

Drugs / interventions tested

• Intervention Participants

Conditions studied

• Cancer — all drugs for Cancer →
• Pain Management — all drugs for Pain Management →
• Opioid Use — all drugs for Opioid Use →

Sponsor

Dana-Farber Cancer Institute

Who can join

21 and older, any sex, with Cancer or Pain Management. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Frequency of Patient Log Ins Primary · 4 Weeks

We will calculate the frequency that patients log in to the application using simple descriptive statistics.

Group	Value	95% CI
Intervention Participants	14	9 – 17

Frequency of Symptom Survey Completion Primary · 4 weeks

We will calculate the number of times patients completed a symptom survey on app during their 28 days on study. Patients could complete up to one symptom survey per day on study.

Group	Value	95% CI
Intervention Participants	8	5 – 14

E-scale Acceptability Secondary · 4 Weeks

Patients will rate overall acceptability of the application using a modified acceptability e-scale. This 6-item measure asks patients to rate the app on ease of use, understandability, enjoyment, helpfulness, time spent, and overall satisfaction, on a 1 to 5 Likert scale. Items are summed to for a total score, ranging from 6 to 30 with 30 being the highest acceptability score.

Group	Value	95% CI
Intervention Participants	24	± 4.37

Usability Secondary · 4 Weeks

Patients will complete a validated 10-item system usability scale (SUS) with total scores ranging from 0-100, where a score of 100 being the best possible usability score.

Group	Value	95% CI
Intervention Participants	78.3	± 16.2

Adverse events — posted to ClinicalTrials.gov

Time frame: 1 year. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Intervention Participants

Serious: 0/20 (0%)

Deaths: 0/20

Other adverse events (1 terms — click to expand)

Reaction	System	Intervention Participants
Consent form error	Social circumstances	—

Data from ClinicalTrials.gov NCT03717402 adverse events section.

Sponsor's own description

The purpose of the study is to develop the STAMP app (Smartphone Technology to Alleviate Malignant Pain). This app will be used by patients with advanced cancer to track symptoms and receive tailored symptom management advice.

This is a single arm pilot feasibility study of the application among patients with advanced cancer and chronic pain who are using opioids in the home setting. Patients will be asked to use the application for a four week period. Clinicians responsible for the patients' pain management will be asked to review alerts from the STAMP system and respond accordingly. The primary outcomes of the study relate to feasibility and acceptability.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. MyPainPal, a Novel mHealth App to Improve Pain in Patients With Advanced Cancer: Single-Arm Pilot Study.
   Azizoddin DR, Hassett M, Anderson KS, Kessler D, et al · · 2025 · PMID 41468579 · DOI 10.2196/79942